Jer-Hwa Chang

Abstract Incorporating pharmacogenetics into clinical practice promises to improve therapeutic outcomes by optimizing drug selection and dosage based on genetic factors affecting drug response. A key advantage of PGx-guided therapy is to decrease the likelihood of adverse events.

Methods In this retrospective multicentre cohort study, we used the Taipei Medical University Clinical Research Database (TMUCRD), which comprises electronic medical records from three affiliated teaching hospitals: Taipei Medical University Hospital, Wan Fang Hospital and Shuang Ho Hospital. These three hospitals are located in the Greater Taipei area of Taiwan, serving populations of 206 014, 259 735 and 406 183 residents, respectively.

Male 8-week-old C57BL/6 JNarl mice were procured from the National Laboratory Animal Center (Taipei, Taiwan). The B6.129S-Sftpctm1(cre/ERT2)Blh/J (Stock no: #028054) and B6.Cg-Gt(ROSA)26Sortm14(CAG−tdTomato)Hze/J (Stock no: #007914) mice were obtained from The Jackson Laboratory and bred to produce B6.Sftpc-CreERT2;Ai14(RCL-tdT)-D mice in Biolasco Taiwan. Both male and female 7-week-old B6.Sftpc-CreERT2;Ai14(RCL-tdT)-D mice were used in the experiment. All mice obtained were included in the study.